Endo International plc (ENDP) PT Raised to $19 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Endo International (ENDP): Vasopressin Headlines Likely Worse than Reality - Citi
August 13, 2018 1:30 PM EDTCiti analyst Liav Abraham weighed in on Endo International plc (NASDAQ: ENDP) following news Athenex lanched a compounded Vasopressin. Abraham said the headline is likely worse than reality.
The firm reiterated a Buy rating and price target of $19.00
For an analyst... More
Endo International (ENDP) Weakness on Compounded Vasopressin Launch Bears Watching FDA Action - RBC
August 13, 2018 11:39 AM EDTThe downside in Endo International (NASDAQ: ENDP) (-2.7%) is related to news Athenex (NASDAQ: ATNX) announced that it had launched compounded Vasopressin injection (i.e. Vasostrict) in ready-to-use premix IV bags via Section 503B of the DQSA, RBC... More
RBC Capital Upgrades Endo International plc (ENDP) to Outperform on Cycle Up-Turn
August 13, 2018 4:51 AM EDT(Updated - August 13, 2018 7:15 AM EDT)
(updated to add analyst comments)
RBC Capital analyst Randall Stanicky upgraded Endo International plc (NASDAQ: ENDP) from Sector Perform to Outperform with a price target of $26.00 (from $8.00).
Stanicky said the upgrade is in... More
